Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE40.8300
- TODAY'S CHANGE (%)0.3500 (0.8646%)
- Bid / Lots40.8000/ 1
- Ask / Lots40.9200/ 4
- Open / Previous Close41.0500 / 40.4800
- Day Range
- 52 Week Range
- Volume137,693
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1843 | 41.05 |
| 09:36 ET | 200 | 41.72 |
| 09:38 ET | 100 | 41.76 |
| 09:41 ET | 1000 | 41.01 |
| 09:43 ET | 100 | 41.23 |
| 09:45 ET | 100 | 41.19 |
| 09:48 ET | 599 | 40.66 |
| 09:50 ET | 600 | 40.72 |
| 09:52 ET | 591 | 40.7 |
| 09:54 ET | 100 | 40.8 |
| 09:56 ET | 300 | 40.63 |
| 09:59 ET | 651 | 40.8 |
| 10:01 ET | 300 | 40.82 |
| 10:03 ET | 100 | 40.98 |
| 10:06 ET | 200 | 41.045 |
| 10:10 ET | 1147 | 41.55 |
| 10:12 ET | 825 | 41.93 |
| 10:14 ET | 1154 | 41.94 |
| 10:15 ET | 679 | 41.935 |
| 10:17 ET | 1543 | 42.395 |
| 10:19 ET | 5265 | 42.08 |
| 10:21 ET | 200 | 41.86 |
| 10:24 ET | 314 | 41.77 |
| 10:26 ET | 200 | 41.75 |
| 10:28 ET | 400 | 41.9 |
| 10:30 ET | 920 | 41.675 |
| 10:32 ET | 405 | 41.56 |
| 10:33 ET | 100 | 41.44 |
| 10:37 ET | 1100 | 41.23 |
| 10:44 ET | 300 | 41.25 |
| 10:46 ET | 200 | 41.28 |
| 10:48 ET | 382 | 41.285 |
| 10:50 ET | 1082 | 41.295 |
| 10:53 ET | 200 | 41.42 |
| 10:55 ET | 746 | 41.36 |
| 10:57 ET | 200 | 41.305 |
| 11:00 ET | 3303 | 41.305 |
| 11:02 ET | 900 | 41.35 |
| 11:04 ET | 834 | 41.29 |
| 11:06 ET | 600 | 41.19 |
| 11:08 ET | 100 | 41.135 |
| 11:09 ET | 100 | 41.16 |
| 11:11 ET | 1300 | 41.15 |
| 11:13 ET | 800 | 41.31 |
| 11:15 ET | 100 | 41.28 |
| 11:18 ET | 812 | 41.215 |
| 11:22 ET | 600 | 41.255 |
| 11:24 ET | 100 | 41.235 |
| 11:26 ET | 320 | 41.24 |
| 11:31 ET | 100 | 41.305 |
| 11:33 ET | 1000 | 41.355 |
| 11:36 ET | 500 | 41.38 |
| 11:38 ET | 1641 | 41.22 |
| 11:40 ET | 904 | 41.2 |
| 11:42 ET | 200 | 41.17 |
| 11:44 ET | 300 | 41.155 |
| 11:49 ET | 500 | 41.16 |
| 11:54 ET | 400 | 41.155 |
| 11:56 ET | 702 | 41.25 |
| 11:58 ET | 100 | 41.32 |
| 12:02 ET | 400 | 41.28 |
| 12:03 ET | 1108 | 41.33 |
| 12:05 ET | 1457 | 41.525 |
| 12:07 ET | 1535 | 41.44 |
| 12:09 ET | 808 | 41.415 |
| 12:14 ET | 1424 | 41.4 |
| 12:16 ET | 100 | 41.36 |
| 12:18 ET | 500 | 41.45 |
| 12:20 ET | 7100 | 41.47 |
| 12:21 ET | 6865 | 41.23 |
| 12:23 ET | 1663 | 41.215 |
| 12:25 ET | 300 | 41.22 |
| 12:27 ET | 300 | 41.17 |
| 12:30 ET | 100 | 41.245 |
| 12:32 ET | 2239 | 41.48 |
| 12:34 ET | 2627 | 41.4525 |
| 12:36 ET | 300 | 41.395 |
| 12:39 ET | 898 | 41.2 |
| 12:45 ET | 100 | 41.305 |
| 12:48 ET | 100 | 41.3 |
| 12:52 ET | 300 | 41.38 |
| 12:54 ET | 200 | 41.355 |
| 12:56 ET | 200 | 41.43 |
| 12:57 ET | 100 | 41.47 |
| 12:59 ET | 100 | 41.48 |
| 01:01 ET | 424 | 41.42 |
| 01:03 ET | 1400 | 41.52 |
| 01:06 ET | 100 | 41.53 |
| 01:08 ET | 609 | 41.4875 |
| 01:10 ET | 451 | 41.37 |
| 01:12 ET | 3909 | 41.395 |
| 01:14 ET | 100 | 41.415 |
| 01:17 ET | 100 | 41.3975 |
| 01:21 ET | 700 | 41.39 |
| 01:24 ET | 1908 | 41.285 |
| 01:32 ET | 100 | 41.205 |
| 01:33 ET | 1940 | 41.045 |
| 01:35 ET | 4649 | 41.045 |
| 01:37 ET | 100 | 41.015 |
| 01:42 ET | 200 | 41.015 |
| 01:44 ET | 200 | 40.89 |
| 01:46 ET | 100 | 40.885 |
| 01:48 ET | 100 | 40.83 |
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
*DJ Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow JonesXenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.1B | -15.1x | --- |
Iovance Biotherapeutics Inc | 3.0B | -6.0x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.2x | --- |
Biohaven Ltd | 3.0B | -5.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 3.0B | -31.1x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -15.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
